<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03398421</url>
  </required_header>
  <id_info>
    <org_study_id>206874</org_study_id>
    <nct_id>NCT03398421</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib</brief_title>
  <official_title>A Single Centre, Open Label, One Sequence, Cross-over Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Single Inhaled Doses of Nemiralisib in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nemiralisib is a potent anti-inflammatory agent for the treatment of chronic obstructive
      pulmonary disease (COPD) and other inflammatory lung diseases. The Cytochrome P450 3A4
      (CYP3A4) is a major route of clearance for nemiralisib. The co-administration of drug
      therapies, which modulate CYP3A4, may alter the exposure of nemiralisib. Hence, this clinical
      drug interaction study with itraconazole (a potent CYP3A4 inhibitor) is required. The study
      will evaluate the PK, safety and tolerability of nemiralisib when administered alone and when
      administered concomitantly with repeat doses of itraconazole in healthy males and females.
      Subjects will receive treatment with nemiralisib alone in Period 1 and itraconazole followed
      by nemiralisib in Period 2 in single sequence crossover manner. Approximately 20 subjects
      will be enrolled such that approximately 16 evaluable subjects complete the study. Each
      subject will participate in the study for approximately 7 weeks including screening visit, 2
      treatment periods and a follow up visit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 17, 2018</start_date>
  <completion_date type="Actual">March 3, 2018</completion_date>
  <primary_completion_date type="Actual">March 3, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subjects will receive nemiralisib alone on Day 1 in Period 1 and itraconazole from Day 1 to Day 10 followed by nemiralisib on Day 5 in Period 2.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This will be an open-label study. Hence, there will be no masking.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC [0-infinity]) of nemiralisib following administration of itraconazole in Period 2</measure>
    <time_frame>Pre-dose, and 5, 30 minutes, 2 , 6, 12, 24, 48, 72, 96, 120 and 144 hours post-dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis of nemiralisib following repeat doses of itraconazole.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve from time zero to t (AUC [0-t]) of nemiralisib following administration of itraconazole in Period 2</measure>
    <time_frame>Pre-dose, and 5, 30 minutes, 2 , 6, 12, 24, 48, 72, 96, 120 and 144 hours post-dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis of nemiralisib following repeat doses of itraconazole.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of nemiralisib following administration of itraconazole in Period 2</measure>
    <time_frame>Pre-dose, and 5, 30 minutes, 2 , 6, 12, 24, 48, 72, 96, 120 and 144 hours post-dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis of nemiralisib following repeat doses of itraconazole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of nemiralisib following administration of itraconazole in Period 2</measure>
    <time_frame>Pre-dose, and 5, 30 minutes, 2 , 6, 12, 24, 48, 72, 96, 120 and 144 hours post-dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis of nemiralisib following repeat doses of itraconazole.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal phase half-life (T1/2) of nemiralisib following administration of itraconazole in Period 2</measure>
    <time_frame>Pre-dose, and 5, 30 minutes, 2 , 6, 12, 24, 48, 72, 96, 120 and 144 hours post-dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis of nemiralisib following repeat doses of itraconazole</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events (AEs)</measure>
    <time_frame>Up to 41 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study subject, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with serious AEs (SAEs)</measure>
    <time_frame>Screening and up to 41 days</time_frame>
    <description>Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment will be categorized as SAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal clinical chemistry laboratory parameters</measure>
    <time_frame>Up to 41 days</time_frame>
    <description>Clinical chemistry parameters will be analyzed as a measure of safety including blood urea nitrogen (BUN), potassium, aspartate aminotransferase (AST)/Serum Glutamic-Oxaloacetic Transaminase (SGOT), total and direct bilirubin, creatinine, sodium, alanine aminotransferase (ALT)/Serum Glutamic-Pyruvic Transaminase (SGPT), total protein, glucose, calcium and alkaline phosphatase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal hematology laboratory parameters</measure>
    <time_frame>Up to 41 days</time_frame>
    <description>Hematology parameters will be analyzed as a measure of safety including platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, percent reticulocytes, neutrophils, lymphocytes, monocytes, eosinophils and basophils.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal values for urinalysis</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Urinalysis parameters will be analyzed including specific gravity. The dipstick method will be used to analyze potential of hydrogen (pH), glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase. Microscopic examination will be performed if blood or protein is abnormal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal values for blood pressure</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Systolic and diastolic blood pressure will be measured in a supine or semi-supine position after 5 minutes rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal values for body temperature</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Body temperature will be measured in a supine or semi-supine position after at least a 5 minutes rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal pulse rate</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Pulse rate will be measured in a supine or semi-supine position after 5 minutes rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal respiratory rate</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Respiratory rate will be measured in a supine or semi-supine position after at least a 5 minutes rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal electrocardiogram (ECG) findings</measure>
    <time_frame>Up to 41 days</time_frame>
    <description>A 12-lead ECGs will be measured in a supine or semi-supine position after 5 minutes rest at each time point using ECG machine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in 1 second (FEV1) following doing with nemiralisib when dosed alone and concomitantly with itraconazole</measure>
    <time_frame>Up to Day 4</time_frame>
    <description>FEV1 is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 is a measure of lung function which will be assessed by spirometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-infinity) of itraconazole when co-administered with nemiralisib in Period 2</measure>
    <time_frame>Pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and Day 5; 24 hours post-dose on Day 5</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis of itraconazole when co-administered with nemiralisib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-infinity) of hydroxy-itraconazole when co-administered with nemiralisib in Period 2</measure>
    <time_frame>Pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and Day 5; 24 hours post-dose on Day 5</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis of hydroxy-itraconazole when co-administered with nemiralisib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-t) of itraconazole when co-administered with nemiralisib in Period 2</measure>
    <time_frame>Pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and Day 5; 24 hours post-dose on Day 5</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis of itraconazole when co-administered with nemiralisib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-t) of hydroxy-itraconazole when co-administered with nemiralisib in Period 2</measure>
    <time_frame>Pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and Day 5; 24 hours post-dose on Day 5</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis of hydroxy-itraconazole when co-administered with nemiralisib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of itraconazole when co-administered with nemiralisib in Period 2</measure>
    <time_frame>Pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and Day 5; 24 hours post-dose on Day 5</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis of itraconazole when co-administered with nemiralisib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of hydroxy-itraconazole when co-administered with nemiralisib in Period 2</measure>
    <time_frame>Pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and Day 5; 24 hours post-dose on Day 5</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis of hydroxy-itraconazole when co-administered with nemiralisib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of itraconazole when co-administered with nemiralisib in Period 2</measure>
    <time_frame>Pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and Day 5; 24 hours post-dose on Day 5</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis of itraconazole when co-administered with nemiralisib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of hydroxy-itraconazole when co-administered with nemiralisib in Period 2</measure>
    <time_frame>Pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and Day 5; 24 hours post-dose on Day 5</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis of hydroxy-itraconazole when co-administered with nemiralisib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of itraconazole when co-administered with nemiralisib in Period 2</measure>
    <time_frame>Pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and Day 5; 24 hours post-dose on Day 5</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis of itraconazole when co-administered with nemiralisib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of hydroxy-itraconazole when co-administered with nemiralisib in Period 2</measure>
    <time_frame>Pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and Day 5; 24 hours post-dose on Day 5</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis of hydroxy-itraconazole when co-administered with nemiralisib.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Subjects receiving nemiralisib and itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive a single dose of 100 micrograms (mcg) nemiralisib on Day 1 in Period 1. Subjects will also receive a single dose of 200 milligrams (mg) itraconazole in the morning from Day 1 to Day 10 and single dose of 100 mcg nemiralisib on Day 5, one hour after the dose of itraconazole in Period 2. There will be a washout of at least 14 days between the administration of nemiralisib in Period 1 and Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nemiralisib</intervention_name>
    <description>Nemiralisib will be given as 100 mcg via ELLIPTA Dry Powder Inhaler with 30 doses per inhaler/ 100 mcg total dose. ELLIPTAÂ® is a registered trademark of GlaxoSmithKline group of companies.</description>
    <arm_group_label>Subjects receiving nemiralisib and itraconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Itraconazole will be given as 100 mg per capsule per day administered orally with water</description>
    <arm_group_label>Subjects receiving nemiralisib and itraconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be 18 to 75 years of age inclusive, at the time of signing the informed
             consent.

          -  Subjects who are overtly healthy as determined by medical evaluation including medical
             history, physical examination, laboratory tests, and cardiac evaluation.

          -  Normal spirometry at Screening (FEV1 and forced vital capacity [FVC] &gt;=80 percent of
             predicted. Measurements to be taken in triplicate. The highest value of each
             individual component must be &gt;=80 percent of predicted).

          -  A subject with a clinical abnormality or laboratory parameter(s) (except for liver
             function tests) outside the reference range for the population being studied may be
             included only if the investigator, in consultation with the medical monitor if needed,
             agree and document that the finding is unlikely to introduce additional risk factors
             and will not interfere with the study procedures.

          -  Body weight &gt;50 kilograms (kg) and body mass index (BMI) within the range 18.0-35.0 kg
             per meter square (kg/m^2) (inclusive).

          -  Male and/or female: A male subject must agree to use contraception during the
             treatment period and for at least 10 days after the last dose of study treatment and
             refrain from donating sperm during this period; a female subject is eligible to
             participate if she is not pregnant, not breastfeeding, and not a woman of childbearing
             potential (WOCBP).

          -  Capable of giving signed informed consent.

        Exclusion Criteria:

          -  History or presence of cardiovascular, respiratory (except childhood asthma, which has
             now remitted), hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric
             or neurological disorders capable of significantly altering the absorption,
             metabolism, or elimination of drugs; constituting a risk when taking the study
             treatment; or interfering with the interpretation of data.

          -  Abnormal blood pressure.

          -  Liver function test results above the upper limit of normal (ULN).

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  QT interval corrected for heart rate by Fridericia's formula (QTcF) &gt;450 milliseconds
             (msec).

          -  Past or intended use of over-the-counter or prescription medication including herbal
             medications within 14 days prior to dosing.

          -  Participation in the study would result in loss of blood or blood products in excess
             of 500 milliliter (mL) within 90 days.

          -  Exposure to more than 4 new chemical entities within 12 months prior to the first
             dosing day.

          -  Current enrolment or past participation within the last 30 days before signing of
             consent in this or any other clinical study involving an investigational study
             treatment or any other type of medical research.

          -  Presence of Hepatitis B surface antigen (HBsAg) at screening or positive Hepatitis C
             antibody test result at screening.

          -  Positive Hepatitis C ribonucleic acid (RNA) test result at screening or within 3
             months prior to first dose of study treatment.

          -  Positive human immunodeficiency virus (HIV) antibody test (according to local
             policies).

          -  Positive drug/alcohol test at screening or on admission (Day -1).

          -  Regular use of known drugs of abuse.

          -  Regular alcohol consumption within 6 months prior to the study defined as: an average
             weekly intake of &gt;14 drinks for males or &gt;7 drinks for females. One drink is
             equivalent to 12 grams (g) of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL)
             of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.

          -  Urinary cotinine levels indicative of smoking or history of regular use of tobacco- or
             nicotine-containing products within 6 months of screening, or a total pack year
             history of &gt;5 pack years. [number of pack years = (number of cigarettes per day/20) x
             number of years smoked].

          -  Sensitivity to any of the study treatments, or components thereof (including lactose
             and Magnesium Stearate), or drug or other allergy that, in the opinion of the
             investigator or medical monitor, contraindicates participation in the study.

          -  Unwillingness to follow the lifestyle restrictions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>January 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2018</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nemiralisib</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Itraconazole</keyword>
  <keyword>Drug-drug Interaction</keyword>
  <keyword>Cross-over</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

